Stereotactic Radiotherapy Treatment for Treatment-resistant Depression
This study is an clinical trial aimed at evaluating the effectiveness and safety of stereotactic radiotherapy for treatment-resistant depression
| Condition(s) | Treatment-Resistant Depression, Depressive Disorder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study is an clinical trial aimed at evaluating the effectiveness and safety of stereotactic radiotherapy for treatment-resistant depression |
| Who can participate | Inclusion Criteria: * Outpatients or inpatients aged 18 to 50 years (inclusive), regardless of gender. * Meet the diagnostic criteria for Major Depressive Disorder (MDD), recurrent, without psychotic features, as defined by The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). * Documented treatment-resistant depression, defined as a lack of clinically meaningful response (less than 50% improvement in depressive symptoms) to at least two adequate antidepressant trials during the current episode, as recorded by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ). An adequate trial requires sufficient dosage (within the recommended therapeutic range) and duration (at least 6 weeks). The current episode must involve at leas |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Lead sponsor | Capital Medical University |
| Locations | Beijing, China |
| Start date | 2026-01-26 |
| NCT ID | NCT07274917 |
| Official listing | https://clinicaltrials.gov/study/NCT07274917 |